Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6542-6559

  Hiller, Christine ^a   Kühhorn, Julia ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENIC AMINE; DIMER; G PROTEIN COUPLED RECEPTOR; LIGAND;

CROSS REACTION; DIMERIZATION; INTRACELLULAR SIGNALING; NONHUMAN; PHOTON; PHYSIOLOGICAL PROCESS; REVIEW;

BIOPHYSICS; DIMERIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; LIGANDS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84883036652     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4004335     Document Type: Review

References (165)

1. Milligan, G. G protein-coupled receptor dimerisation: molecular basis and relevance to function Biochim. Biophys. Acta 2007, 1768, 825-835
2. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors Nat. Rev. Neurosci. 2001, 2, 274-286
3. Devi, L. A. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking Trends Pharmacol. Sci. 2001, 22, 532-537
4. George, S. R.; O'Dowd, B. F.; Lee, S. R. G-protein-coupled receptor oligomerization and its potential for drug discovery Nat. Rev. Drug Discovery 2002, 1, 808-820
5. Milligan, G. G protein-coupled receptor dimerization: function and ligand pharmacology Mol. Pharmacol. 2004, 66, 1-7
6. Ferre, S.; Ciruela, F.; Woods, A. S.; Lluis, C.; Franco, R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system Trends Neurosci. 2007, 30, 440-446
7. Milligan, G. A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization Br. J. Pharmacol. 2008, 153, 216-229
8. Maurice, P.; Kamal, M.; Jockers, R. Asymmetry of GPCR oligomers supports their functional relevance Trends Pharmacol. Sci. 2011, 32, 514-520
9. Prinster, S. C.; Hague, C.; Hall, R. A. Heterodimerization of G protein-coupled receptors: specificity and functional significance Pharmacol. Rev. 2005, 57, 289-298
10. Agnati, L. F.; Ferre, S.; Lluis, C.; Franco, R.; Fuxe, K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons Pharmacol. Rev. 2003, 55, 509-550
11. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation J. Biol. Chem. 1996, 271, 16384-16392
12. Jordan, B. A.; Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function Nature 1999, 399, 697-700
13. Hillion, J.; Canals, M.; Torvinen, M.; Casado, V.; Scott, R.; Terasmaa, A.; Hansson, A.; Watson, S.; Olah, M. E.; Mallol, J.; Canela, E. I.; Zoli, M.; Agnati, L. F.; Ibanez, C. F.; Lluis, C.; Franco, R.; Ferre, S.; Fuxe, K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors J. Biol. Chem. 2002, 277, 18091-18097
14. Park, P. S. H.; Wells, J. W. Oligomeric potential of the M2 muscarinic cholinergic receptor J. Neurochem. 2004, 90, 537-548
15. Koschatzky, S.; Tschammer, N.; Gmeiner, P. Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics ACS Chem. Neurosci. 2011, 2, 308-316
16. Milligan, G.; Bouvier, M. Methods to monitor the quaternary structure of G protein-coupled receptors FEBS J. 2005, 272, 2914-2925
17. Persani, L.; Calebiro, D.; Bonomi, M. Technology Insight: modern methods to monitor protein-protein interactions reveal functional TSH receptor oligomerization Nat. Clin. Pract. Endocrinol. Metab. 2007, 3, 180-190
18. Guo, W.; Shi, L.; Javitch, J. A. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer J. Biol. Chem. 2003, 278, 4385-4388
19. Guo, W.; Shi, L.; Filizola, M.; Weinstein, H.; Javitch, J. A. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17495-17500
20. Herrick-Davis, K.; Grinde, E.; Mazurkiewicz, J. E. Biochemical and biophysical characterization of serotonin 5-HT2C receptor homodimers on the plasma membrane of living cells Biochemistry 2004, 43, 13963-13971
21. Angers, S.; Salahpour, A.; Joly, E.; Hilairet, S.; Chelsky, D.; Dennis, M.; Bouvier, M. Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET) Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3684-3689
22. Shenton, F. C.; Hann, V.; Chazot, P. L. Evidence for native and cloned H3 histamine receptor higher oligomers Inflamm. Res. 2005, 54, 48-49
23. Cottet, M.; Faklaris, O.; Maurel, D.; Scholler, P.; Doumazane, E.; Trinquet, E.; Pin, J. P.; Durroux, T. BRET and time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues Front. Endocrinol. 2012, 3, 92
24. Maurel, D.; Comps-Agrar, L.; Brock, C.; Rives, M. L.; Bourrier, E.; Ayoub, M. A.; Bazin, H.; Tinel, N.; Durroux, T.; Prezeau, L.; Trinquet, E.; Pin, J. P. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization Nat. Methods 2008, 5, 561-567
25. Goddard, A. D.; Watts, A. Contributions of fluorescence techniques to understanding G protein-coupled receptor dimerisation Biophys. Rev. 2012, 4, 291-298
26. Albizu, L.; Cottet, M.; Kralikova, M.; Stoev, S.; Seyer, R.; Brabet, I.; Roux, T.; Bazin, H.; Bourrier, E.; Lamarque, L.; Breton, C.; Rives, M. L.; Newman, A.; Javitch, J.; Trinquet, E.; Manning, M.; Pin, J. P.; Mouillac, B.; Durroux, T. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues Nat. Chem. Biol. 2010, 6, 587-594
27. Reits, E. A. J.; Neefjes, J. J. From fixed to FRAP: measuring protein mobility and activity in living cells Nat. Cell Biol. 2001, 3, 145-147
28. Dorsch, S.; Klotz, K. N.; Engelhardt, S.; Lohse, M. J.; Bunemann, M. Analysis of receptor oligomerization by FRAP microscopy Nat. Methods 2009, 6, 225-230
29. Nagai, T.; Ibata, K.; Park, E. S.; Kubota, M.; Mikoshiba, K.; Miyawaki, A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications Nat. Biotechnol. 2002, 20, 87-90
30. Rizzo, M. A.; Springer, G. H.; Granada, B.; Piston, D. W. An improved cyan fluorescent protein variant useful for FRET Nat. Biotechnol. 2004, 22, 445-449
31. Shaner, N. C.; Campbell, R. E.; Steinbach, P. A.; Giepmans, B. N. G.; Palmer, A. E.; Tsien, R. Y. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein Nat. Biotechnol. 2004, 22, 1567-1572
32. Kerppola, T. K. Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells Annu Rev Biophys 2008, 37, 465-487
33. Urizar, E.; Yano, H.; Kolster, R.; Gales, C.; Lambert, N.; Javitch, J. A. CODA-RET reveals functional selectivity as a result of GPCR heteromerization Nat. Chem. Biol. 2011, 7, 624-630
34. Mattheyses, A. L.; Simon, S. M.; Rappoport, J. Z. Imaging with total internal reflection fluorescence microscopy for the cell biologist J. Cell Sci. 2010, 123, 3621-3628
35. Hern, J. A.; Baig, A. H.; Mashanov, G. I.; Birdsall, B.; Corrie, J. E. T.; Lazareno, S.; Molloy, J. E.; Birdsall, N. J. M. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2693-2698
36. Calebiro, D.; Rieken, F.; Wagner, J.; Sungkaworn, T.; Zabel, U.; Borzi, A.; Cocucci, E.; Zurn, A.; Lohse, M. J. Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 743-748
37. Milligan, G.; Parenty, G.; Stoddart, L. A.; Lane, J. R. Novel pharmacological applications of G-protein-coupled receptor-G protein fusions Curr. Opin. Pharmacol. 2007, 7, 521-526
38. Han, Y.; Moreira, I. S.; Urizar, E.; Weinstein, H.; Javitch, J. A. Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation Nat. Chem. Biol. 2009, 5, 688-695
39. Smith, N. J.; Milligan, G. Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes Pharmacol. Rev. 2010, 62, 701-725
40. Wu, B.; Chien, E. Y.; Mol, C. D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F. C.; Hamel, D. J.; Kuhn, P.; Handel, T. M.; Cherezov, V.; Stevens, R. C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 2010, 330, 1066-1071
41. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-326
42. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human κ-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
43. Pin, J. P.; Neubig, R.; Bouvier, M.; Devi, L.; Filizola, M.; Javitch, J. A.; Lohse, M. J.; Milligan, G.; Palczewski, K.; Parmentier, M.; Spedding, M. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers Pharmacol. Rev. 2007, 59, 5-13
44. Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H. H.; Pintar, J. E.; Devi, L. A. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 5135-5139
45. Springael, J. Y.; Le Minh, P. N.; Urizar, E.; Costagliola, S.; Vassart, G.; Parmentier, M. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers Mol. Pharmacol. 2006, 69, 1652-1661
46. Vilardaga, J. P.; Nikolaev, V. O.; Lorenz, K.; Ferrandon, S.; Zhuang, Z. J.; Lohse, M. J. Conformational cross-talk between α2A-adrenergic and μ-opioid receptors controls cell signaling Nat. Chem. Biol. 2008, 4, 126-131
47. AbdAlla, S.; Lother, H.; Quitterer, U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration Nature 2000, 407, 94-98
48. Rashid, A. J.; So, C. H.; Kong, M. M. C.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B. F.; George, S. R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of G(q)/11 in the striatum Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 654-659
49. Jarrahian, A.; Watts, V. J.; Barker, E. L. D2 dopamine receptors modulate Gα-subunit coupling of the CB1 cannabinoid receptor J. Pharmacol. Exp. Ther. 2004, 308, 880-886
50. Rozenfeld, R.; Devi, L. A. Receptor heterodimerization leads to a switch in signaling: β-arrestin2-mediated ERK activation by μ-δ opioid receptor heterodimers FASEB J. 2007, 21, 2455-2465
51. Abul-Husn, N. S.; Sutak, M.; Milne, B.; Jhamandas, K. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists Br. J. Pharmacol. 2007, 151, 877-887
52. Zhu, Y.; King, M. A.; Schuller, A. G.; Nitsche, J. F.; Reidl, M.; Elde, R. P.; Unterwald, E.; Pasternak, G. W.; Pintar, J. E. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice Neuron 1999, 24, 243-252
53. Bohn, L. M.; Gainetdinov, R. R.; Lin, F. T.; Lefkowitz, R. J.; Caron, M. G. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence Nature 2000, 408, 720-723
54. Lee, S. P.; O'Dowd, B. F.; Ng, G. Y.; Varghese, G.; Akil, H.; Mansour, A.; Nguyen, T.; George, S. R. Inhibition of cell surface expression by mutant receptors demonstrates that D2 dopamine receptors exist as oligomers in the cell Mol. Pharmacol. 2000, 58, 120-128
55. Zhu, X.; Wess, J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function Biochemistry 1998, 37, 15773-15784
56. Salahpour, A.; Angers, S.; Mercier, J. F.; Lagace, M.; Marullo, S.; Bouvier, M. Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting J. Biol. Chem. 2004, 279, 33390-33397
57. Wilson, S.; Wilkinson, G.; Milligan, G. The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities J. Biol. Chem. 2005, 280, 28663-28674
58. Chalothorn, D.; McCune, D. F.; Edelmann, S. E.; Garcia-Cazarin, M. L.; Tsujimoto, G.; Piascik, M. T. Differences in the cellular localization and agonist-mediated internalization properties of the α1-adrenoceptor subtypes Mol. Pharmacol. 2002, 61, 1008-1016
59. Uberti, M. A.; Hall, R. A.; Minneman, K. P. Subtype-specific dimerization of α1-adrenoceptors: effects on receptor expression and pharmacological properties Mol. Pharmacol. 2003, 64, 1379-1390
60. He, S. Q.; Zhang, Z. N.; Guan, J. S.; Liu, H. R.; Zhao, B.; Wang, H. B.; Li, Q.; Yang, H.; Luo, J.; Li, Z. Y.; Wang, Q.; Lu, Y. J.; Bao, L.; Zhang, X. Facilitation of mu-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation Neuron 2011, 69, 120-131
61. Lukasiewicz, S.; Polit, A.; Kedracka-Krok, S.; Wedzony, K.; Mackowiak, M.; Dziedzicka-Wasylewska, M. Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors Biochim. Biophys. Acta 2010, 1803, 1347-1358
62. Albizu, L.; Holloway, T.; Gonzalez-Maeso, J.; Sealfon, S. C. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors Neuropharmacology 2011, 61, 770-777
63. Berthouze, M.; Ayoub, M.; Russo, O.; Rivail, L.; Sicsic, S.; Fischmeister, R.; Berque-Bestel, I.; Jockers, R.; Lezoualc'h, F. Constitutive dimerization of human serotonin 5-HT4 receptors in living cells FEBS Lett. 2005, 579, 2973-2980
64. Stanasila, L.; Perez, J. B.; Vogel, H.; Cotecchia, S. Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization J. Biol. Chem. 2003, 278, 40239-40251
65. Carrillo, J. J.; Pediani, J.; Milligan, G. Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins J. Biol. Chem. 2003, 278, 42578-42587
66. Hague, C.; Uberti, M. A.; Chen, Z.; Hall, R. A.; Minneman, K. P. Cell surface expression of alpha1D-adrenergic receptors is controlled by heterodimerization with alpha1B-adrenergic receptors J. Biol. Chem. 2004, 279, 15541-15549
67. Hague, C.; Lee, S. E.; Chen, Z.; Prinster, S. C.; Hall, R. A.; Minneman, K. P. Heterodimers of alpha1B- and alpha1D-adrenergic receptors form a single functional entity Mol. Pharmacol. 2006, 69, 45-55
68. Xu, J.; He, J.; Castleberry, A. M.; Balasubramanian, S.; Lau, A. G.; Hall, R. A. Heterodimerization of alpha 2A- and beta 1-adrenergic receptors J. Biol. Chem. 2003, 278, 10770-10777
69. Ciruela, F.; Casado, V.; Rodrigues, R. J.; Lujan, R.; Burgueno, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S. R.; Mallol, J.; Cortes, A.; Canela, E. I.; Lopez-Gimenez, J. F.; Milligan, G.; Lluis, C.; Cunha, R. A.; Ferre, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers J. Neurosci. 2006, 26, 2080-2087
70. Romano, F. D.; MacDonald, S. G.; Dobson, J. G., Jr. Adenosine receptor coupling to adenylate cyclase of rat ventricular myocyte membranes Am. J. Physiol. 1989, 257, H1088-H1095
71. Gerwins, P.; Nordstedt, C.; Fredholm, B. B. Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells Mol. Pharmacol. 1990, 38, 660-666
72. Gines, S.; Hillion, J.; Torvinen, M.; Le Crom, S.; Casado, V.; Canela, E. I.; Rondin, S.; Lew, J. Y.; Watson, S.; Zoli, M.; Agnati, L. F.; Verniera, P.; Lluis, C.; Ferre, S.; Fuxe, K.; Franco, R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8606-8611
73. Carriba, P.; Ortiz, O.; Patkar, K.; Justinova, Z.; Stroik, J.; Themann, A.; Muller, C.; Woods, A. S.; Hope, B. T.; Ciruela, F.; Casado, V.; Canela, E. I.; Lluis, C.; Goldberg, S. R.; Moratalla, R.; Franco, R.; Ferre, S. Striatal adenosine A(2A) and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids Neuropsychopharmacology 2007, 32, 2249-2259
74. Canals, M.; Marcellino, D.; Fanelli, F.; Ciruela, F.; de Benedetti, P.; Goldberg, S. R.; Neve, K.; Fuxe, K.; Agnati, L. F.; Woods, A. S.; Ferre, S.; Lluis, C.; Bouvier, M.; Franco, R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J. Biol. Chem. 2003, 278, 46741-46749
75. Kamiya, T.; Saitoh, O.; Yoshioka, K.; Nakata, H. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells Biochem. Biophys. Res. Commun. 2003, 306, 544-549
76. Tanganelli, S.; Sandager Nielsen, K.; Ferraro, L.; Antonelli, T.; Kehr, J.; Franco, R.; Ferre, S.; Agnati, L. F.; Fuxe, K.; Scheel-Kruger, J. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's disease Parkinsonism Relat. Disord. 2004, 10, 273-280
77. Fuxe, K.; Agnati, L. F.; Jacobsen, K.; Hillion, J.; Canals, M.; Torvinen, M.; Tinner-Staines, B.; Staines, W.; Rosin, D.; Terasmaa, A.; Popoli, P.; Leo, G.; Vergoni, V.; Lluis, C.; Ciruela, F.; Franco, R.; Ferre, S. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease Neurology 2003, 61, 19-23
78. Fuxe, K.; Ferre, S.; Canals, M.; Torvinen, M.; Terasmaa, A.; Marcellino, D.; Goldberg, S. R.; Staines, W.; Jacobsen, K. X.; Lluis, C.; Woods, A. S.; Agnati, L. F.; Franco, R. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function J. Mol. Neurosci. 2005, 26, 209-220
79. AbdAlla, S.; Lother, H.; el Massiery, A.; Quitterer, U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness Nat. Med. 2001, 7, 1003-1009
80. Hansen, J. L.; Hansen, J. T.; Speerschneider, T.; Lyngso, C.; Erikstrup, N.; Burstein, E. S.; Weiner, D. M.; Walther, T.; Makita, N.; Iiri, T.; Merten, N.; Kostenis, E.; Sheikh, S. P. Lack of evidence for AT1R/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: How common is the AT1R/B2R heterodimer? J. Biol. Chem. 2009, 284, 1831-1839
81. Barki-Harrington, L.; Luttrell, L. M.; Rockman, H. A. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo Circulation 2003, 108, 1611-1618
82. Rozenfeld, R.; Gupta, A.; Gagnidze, K.; Lim, M. P.; Gomes, I.; Lee-Ramos, D.; Nieto, N.; Devi, L. A. AT1R-CB(1)R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II EMBO J. 2011, 30, 2350-2363
83. Mercier, J. F.; Salahpour, A.; Angers, S.; Breit, A.; Bouvier, M. Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer J. Biol. Chem. 2002, 277, 44925-44931
84. Zhu, W. Z.; Chakir, K.; Zhang, S.; Yang, D.; Lavoie, C.; Bouvier, M.; Hebert, T. E.; Lakatta, E. G.; Cheng, H.; Xiao, R. P. Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility Circ. Res. 2005, 97, 244-251
85. Jordan, B. A.; Trapaidze, N.; Gomes, I.; Nivarthi, R.; Devi, L. A. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 343-348
86. Wrzal, P. K.; Devost, D.; Petrin, D.; Goupil, E.; Iorio-Morin, C.; Laporte, S. A.; Zingg, H. H.; Hebert, T. E. Allosteric interactions between the oxytocin receptor and the beta2-adrenergic receptor in the modulation of ERK1/2 activation are mediated by heterodimerization Cell. Signalling 2012, 24, 342-350
87. Marcellino, D.; Carriba, P.; Filip, M.; Borgkvist, A.; Frankowska, M.; Bellido, I.; Tanganelli, S.; Muller, C. E.; Fisone, G.; Lluis, C.; Agnati, L. F.; Franco, R.; Fuxe, K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis Neuropharmacology 2008, 54, 815-823
88. Kearn, C. S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol. 2005, 67, 1697-1704
89. Rozenfeld, R.; Bushlin, I.; Gomes, I.; Tzavaras, N.; Gupta, A.; Neves, S.; Battini, L.; Gusella, G. L.; Lachmann, A.; Ma'ayan, A.; Blitzer, R. D.; Devi, L. A. Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons PLoS One 2012, 7, e29239
90. Rios, C.; Gomes, I.; Devi, L. A. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis Br. J. Pharmacol. 2006, 148, 387-395
91. Zheng, Y.; Akgun, E.; Harikumar, K. G.; Hopson, J.; Powers, M. D.; Lunzer, M. M.; Miller, L. J.; Portoghese, P. S. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands J. Med. Chem. 2009, 52, 247-258
92. El-Asmar, L.; Springael, J. Y.; Ballet, S.; Andrieu, E. U.; Vassart, G.; Parmentier, M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers Mol. Pharmacol. 2005, 67, 460-469
93. Chen, C. G.; Li, J.; Bot, G.; Szabo, I.; Rogers, T. J.; Liu-Chen, L. Y. Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor Eur. J. Pharmacol. 2004, 483, 175-186
94. Parenty, G.; Appelbe, S.; Milligan, G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer Biochem. J. 2008, 412, 245-256
95. Hasbi, A.; Nguyen, T.; Fan, T.; Cheng, R.; Rashid, A.; Alijaniaram, M.; Rasenick, M. M.; O'Dowd, B. F.; George, S. R. Trafficking of preassembled opioid mu-delta heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists Biochemistry 2007, 46, 12997-13009
96. George, S. R.; Fan, T.; Xie, Z. D.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B. F. Oligomerization of mu- and delta-opioid receptors-generation of novel functional properties J. Biol. Chem. 2000, 275, 26128-26135
97. Gomes, I.; IJzerman, A. P.; Ye, K.; Maillet, E. L.; Devi, L. A. G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding Mol. Pharmacol. 2011, 79, 1044-1052
98. van Rijn, R. M.; Harvey, J. H.; Brissett, D. I.; DeFriel, J. N.; Whistler, J. L. Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling J. Pharmacol. Exp. Ther. 2013, 344, 179-188
99. So, C. H.; Varghese, G.; Curley, K. J.; Kong, M. M.; Alijaniaram, M.; Ji, X.; Nguyen, T.; O'Dowd, B, F.; George, S. R. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor Mol. Pharmacol. 2005, 68, 568-578
100. Marcellino, D.; Ferre, S.; Casado, V.; Cortes, A.; Le Foll, B.; Mazzola, C.; Drago, F.; Saur, O.; Stark, H.; Soriano, A.; Barnes, C.; Goldberg, S. R.; Lluis, C.; Fuxe, K.; Franco, R. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum J. Biol. Chem. 2008, 283, 26016-26025
101. Fiorentini, C.; Busi, C.; Gorruso, E.; Gotti, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization Mol. Pharmacol. 2008, 74, 59-69
102. Ferrada, C.; Ferre, S.; Casado, V.; Cortes, A.; Justinova, Z.; Barnes, C.; Canela, E. I.; Goldberg, S. R.; Leurs, R.; Lluis, C.; Franco, R. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function Neuropharmacology 2008, 55, 190-197
103. Scarselli, M.; Novi, F.; Schallmach, E.; Lin, R.; Baragli, A.; Colzi, A.; Griffon, N.; Corsini, G. U.; Sokoloff, P.; Levenson, R.; Vogel, Z.; Maggio, R. D2/D3 dopamine receptor heterodimers exhibit unique functional properties J. Biol. Chem. 2001, 276, 30308-30314
104. Maggio, R.; Scarselli, M.; Novi, F.; Millan, M. J.; Corsini, G. U. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole J. Neurochem. 2003, 87, 631-641
105. Rocheville, M.; Lange, D. C.; Kumar, U.; Patel, S. C.; Patel, R. C.; Patel, Y. C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science 2000, 288, 154-157
106. Wang, D.; Sun, X.; Bohn, L. M.; Sadee, W. Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer Mol. Pharmacol. 2005, 67, 2173-2184
107. Pfeiffer, M.; Koch, T.; Schroder, H.; Laugsch, M.; Hollt, V.; Schulz, S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization J. Biol. Chem. 2002, 277, 19762-19772
108. Hu, J.; Thor, D.; Zhou, Y.; Liu, T.; Wang, Y.; McMillin, S. M.; Mistry, R.; Challiss, R. A.; Costanzi, S.; Wess, J. Structural aspects of M(3) muscarinic acetylcholine receptor dimer formation and activation FASEB J. 2012, 26, 604-616
109. Rocheville, M.; Lange, D. C.; Kumar, U.; Sasi, R.; Patel, R. C.; Patel, Y. C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers J. Biol. Chem. 2000, 275, 7862-7869
110. Pfeiffer, M.; Koch, T.; Schroder, H.; Klutzny, M.; Kirscht, S.; Kreienkamp, H. J.; Hollt, V.; Schulz, S. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) J. Biol. Chem. 2001, 276, 14027-14036
111. Terrillon, S.; Barberis, C.; Bouvier, M. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1548-1553
112. Terrillon, S.; Durroux, T.; Mouillac, B.; Breit, A.; Ayoub, M. A.; Taulan, M.; Jockers, R.; Barberis, C.; Bouvier, M. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis Mol. Endocrinol. 2003, 17, 677-691
113. Pei, L.; Li, S.; Wang, M.; Diwan, M.; Anisman, H.; Fletcher, P. J.; Nobrega, J. N.; Liu, F. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects Nat. Med. 2010, 16, 1393-1395
114. Barnes, P. J. Receptor heterodimerization: a new level of cross-talk J. Clin. Invest. 2006, 116, 1210-1212
115. Daniels, D. J.; Lenard, N. R.; Etienne, C. L.; Law, P. Y.; Roerig, S. C.; Portoghese, P. S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 19208-19213
116. Lenard, N. R.; Daniels, D. J.; Portoghese, P. S.; Roerig, S. C. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores Eur. J. Pharmacol. 2007, 566, 75-82
117. Cunningham, K. A.; Anastasio, N. C.; Fox, R. G.; Stutz, S. J.; Bubar, M. J.; Swinford, S. E.; Watson, C. S.; Gilbertson, S. R.; Rice, K. C.; Rosenzweig-Lipson, S.; Moeller, F. G. Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction ACS Chem. Neurosci. 2013, 4, 110-121
118. Waldhoer, M.; Fong, J.; Jones, R. M.; Lunzer, M. M.; Sharma, S. K.; Kostenis, E.; Portoghese, P. S.; Whistler, J. L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9050-9055
119. Yekkirala, A. S.; Lunzer, M. M.; McCurdy, C. R.; Powers, M. D.; Kalyuzhny, A. E.; Roerig, S. C.; Portoghese, P. S. N -Naphthoyl-beta- naltrexamine (NNTA), a highly selective and potent activator of mu/kappa-opioid heteromers Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 5098-5103
120. Yekkirala, A. S.; Banks, M. L.; Lunzer, M. M.; Negus, S. S.; Rice, K. C.; Portoghese, P. S. Clinically employed opioid analgesics produce antinociception via mu-delta opioid receptor heteromers in Rhesus monkeys ACS Chem. Neurosci. 2012, 3, 720-727
121. Kuhhorn, J.; Gotz, A.; Hubner, H.; Thompson, D.; Whistler, J.; Gmeiner, P. Development of a bivalent dopamine D2 receptor agonist J. Med. Chem. 2011, 54, 7911-7919
122. Erez, M.; Takemori, A. E.; Portoghese, P. S. Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites J. Med. Chem. 1982, 25, 847-849
123. Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands as receptor probes Life Sci. 1982, 31, 1283-1286
124. Portoghese, P. S.; Larson, D. L.; Yim, C. B.; Sayre, L. M.; Ronsisvalle, G.; Lipkowski, A. W.; Takemori, A. E.; Rice, K. C.; Tam, S. W. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors J. Med. Chem. 1985, 28, 1140-1141
125. Portoghese, P. S.; Larson, D. L.; Sayre, L. M.; Yim, C. B.; Ronsisvalle, G.; Tam, S. W.; Takemori, A. E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem. 1986, 29, 1855-1861
126. Halazy, S.; Perez, M.; Fourrier, C.; Pallard, I.; Pauwels, P. J.; Palmier, C.; John, G. W.; Valentin, J. P.; Bonnafous, R.; Martinez, J. Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists J. Med. Chem. 1996, 39, 4920-4927
127. Perez, M.; Pauwels, P. J.; Fourrier, C.; Chopin, P.; Valentin, J. P.; John, G. W.; Marien, M.; Halazy, S. Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist Bioorg. Med. Chem. Lett. 1998, 8, 675-680
128. Russo, O.; Berthouze, M.; Giner, M.; Soulier, J. L.; Rivail, L.; Sicsic, S.; Lezoualc'h, F.; Jockers, R.; Berque-Bestel, I. Synthesis of specific bivalent probes that functionally interact with 5-HT4 receptor dimers J. Med. Chem. 2007, 50, 4482-4492
129. Soulier, J. L.; Russo, O.; Giner, M.; Rivail, L.; Berthouze, M.; Ongeri, S.; Maigret, B.; Fischmeister, R.; Lezoualc'h, F.; Sicsic, S.; Berque-Bestel, I. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies J. Med. Chem. 2005, 48, 6220-6228
130. Birnkammer, T.; Spickenreither, A.; Brunskole, I.; Lopuch, M.; Kagermeier, N.; Bernhardt, G.; Dove, S.; Seifert, R.; Elz, S.; Buschauer, A. The bivalent ligand approach leads to highly potent and selective acylguanidine-type histamine H2 receptor agonists J. Med. Chem. 2012, 55, 1147-1160
131. Huber, D.; Hubner, H.; Gmeiner, P. 1,1′-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands J. Med. Chem. 2009, 52, 6860-6870
132. Huber, D.; Lober, S.; Hubner, H.; Gmeiner, P. Bivalent molecular probes for dopamine D2-like receptors Bioorg. Med. Chem. 2012, 20, 455-466
133. Butini, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Kumar, V.; Guarino, E.; Borrelli, G.; Fiorini, I.; Novellino, E.; Fattorusso, C.; Persico, M.; Orteca, N.; Sandager-Nielsen, K.; Jacobsen, T. A.; Madsen, K.; Scheel-Kruger, J.; Gemma, S. Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors J. Med. Chem. 2010, 53, 4803-4807
134. Kuhhorn, J.; Hubner, H.; Gmeiner, P. Bivalent dopamine D2 receptor ligands: synthesis and binding properties J. Med. Chem. 2011, 54, 4896-4903
135. McRobb, F. M.; Crosby, I. T.; Yuriev, E.; Lane, J. R.; Capuano, B. Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation J. Med. Chem. 2012, 55, 1622-1634
136. Gogoi, S.; Biswas, S.; Modi, G.; Antonio, T.; Reith, M. E.; Dutta, A. K. Novel bivalent ligands for D2/D3 dopamine receptors: significant co-operative gain in D2 affinity and potency ACS Med. Chem. Lett. 2012, 3, 991-996
137. Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casado, V.; Cortes, A.; Fanelli, F.; Albericio, F.; Lluis, C.; Franco, R.; Royo, M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers J. Med. Chem. 2009, 52, 5590-5602
138. Jacobson, K. A.; Xie, R.; Young, L.; Chang, L.; Liang, B. T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists J. Biol. Chem. 2000, 275, 30272-30279
139. Tanaka, T.; Nomura, W.; Narumi, T.; Masuda, A.; Tamamura, H. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells J. Am. Chem. Soc. 2010, 132, 15899-15901
140. Choi, W. T.; Kumar, S.; Madani, N.; Han, X.; Tian, S.; Dong, C. Z.; Liu, D.; Duggineni, S.; Yuan, J.; Sodroski, J. G.; Huang, Z.; An, J. A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry Biochemistry 2012, 51, 7078-7086
141. Zhang, Y. N.; Gilliam, A.; Maitra, R.; Damaj, M. I.; Tajuba, J. M.; Seltzman, H. H.; Thomas, B. F. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor J. Med. Chem. 2010, 53, 7048-7060
142. Rajeswaran, W. G.; Cao, Y.; Huang, X. P.; Wroblewski, M. E.; Colclough, T.; Lee, S.; Liu, F.; Nagy, P. I.; Ellis, J.; Levine, B. A.; Nocka, K. H.; Messer, W. S., Jr. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as
143. Cao, Y.; Zhang, M.; Wu, C.; Lee, S.; Wroblewski, M. E.; Whipple, T.; Nagy, P. I.; Takacs-Novak, K.; Balazs, A.; Toros, S.; Messer, W. S., Jr. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl- 1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders J. Med. Chem. 2003, 46, 4273-4286
144. Karellas, P.; McNaughton, M.; Baker, S. P.; Scammells, P. J. Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands J. Med. Chem. 2008, 51, 6128-6137
145. Lalchandani, S. G.; Lei, L.; Zheng, W.; Suni, M. M.; Moore, B. M.; Liggett, S. B.; Miller, D. D.; Feller, D. R. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype J. Pharmacol. Exp. Ther. 2002, 303, 979-984
146. Valant, C.; Sexton, P. M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs Mol. Interventions 2009, 9, 125-135
147. Mohr, K.; Trankle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise Br. J. Pharmacol. 2010, 159, 997-1008
148. Valant, C.; Robert Lane, J.; Sexton, P. M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 153-178
149. Shonberg, J.; Scammells, P. J.; Capuano, B. Design strategies for bivalent ligands targeting GPCRs ChemMedChem. 2011, 6, 963-974
150. Decker, M.; Fulton, B. S.; Zhang, B.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands J. Med. Chem. 2009, 52, 7389-7396
151. Zhang, B.; Zhang, T.; Sromek, A. W.; Scrimale, T.; Bidlack, J. M.; Neumeyer, J. L. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for kappa, mu, and delta opioid receptors Bioorg. Med. Chem. 2011, 19, 2808-2816
152. Bonger, K. M.; van den Berg, R. J.; Knijnenburg, A. D.; Heitman, L. H.; Ijzerman, A. P.; Oosterom, J.; Timmers, C. M.; Overkleeft, H. S.; van der Marel, G. A. Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core Bioorg. Med. Chem. 2008, 16, 3744-3758
153. Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; Konig, B. Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists Bioorg. Med. Chem. 2008, 16, 9858-9866
154. Bhushan, R. G.; Sharma, S. K.; Xie, Z.; Daniels, D. J.; Portoghese, P. S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers J. Med. Chem. 2004, 47, 2969-2972
155. Rivail, L.; Giner, M.; Gastineau, M.; Berthouze, M.; Soulier, J. L.; Fischmeister, R.; Lezoualc'h, F.; Maigret, B.; Sicsic, S.; Berque-Bestel, I. New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket Br. J. Pharmacol. 2004, 143, 361-370
156. Berque-Bestel, I.; Soulier, J. L.; Giner, M.; Rivail, L.; Langlois, M.; Sicsic, S. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors J. Med. Chem. 2003, 46, 2606-2620
157. Zhang, S.; Yekkirala, A.; Tang, Y.; Portoghese, P. S. A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors Bioorg. Med. Chem. Lett. 2009, 19, 6978-6980
158. Daniels, D. J.; Kulkarni, A.; Xie, Z. H.; Bhushan, R. G.; Portoghese, P. S. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes J. Med. Chem. 2005, 48, 1713-1716
159. Portoghese, P. S.; Ronsisvalle, G.; Larson, D. L.; Takemori, A. E. Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers J. Med. Chem. 1986, 29, 1650-1653
160. Bonger, K. M.; Kapoerchan, V. V.; Grotenbreg, G. M.; van Koppen, C. J.; Timmers, C. M.; van der Marel, G. A.; Overkleeft, H. S. Oligoproline helices as structurally defined scaffolds for oligomeric G protein-coupled receptor ligands Org. Biomol. Chem. 2010, 8, 1881-1884
161. Kuemin, M.; Schweizer, S.; Ochsenfeld, C.; Wennemers, H. Effects of terminal functional groups on the stability of the polyproline II structure: a combined experimental and theoretical study J. Am. Chem. Soc. 2009, 131, 15474-15482
162. Yuan, Y.; Arnatt, C. K.; Li, G.; Haney, K. M.; Ding, D.; Jacob, J. C.; Selley, D. E.; Zhang, Y. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5 Org. Biomol. Chem. 2012, 10, 2633-2646
163. Harvey, J. H.; Long, D. H.; England, P. M.; Whistler, J. L. Tuned-affinity bivalent ligands for the characterization of opioid receptor heteromers ACS Med. Chem. Lett. 2012, 3, 640-644
164. Wei, Z. Y.; Brown, W.; Takasaki, B.; Plobeck, N.; Delorme, D.; Zhou, F.; Yang, H.; Jones, P.; Gawell, L.; Gagnon, H.; Schmidt, R.; Yue, S. Y.; Walpole, C.; Payza, K.; St-Onge, S.; Labarre, M.; Godbout, C.; Jakob, A.; Butterworth, J.; Kamassah, A.; Morin, P. E.; Projean, D.; Ducharme, J.; Roberts, E. N, N -Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues J. Med. Chem. 2000, 43, 3895-3905
165. Harikumar, K. G.; Akgun, E.; Portoghese, P. S.; Miller, L. J. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization J. Med. Chem. 2010, 53, 2836-2842